<?xml version='1.0' encoding='utf-8'?>
<document id="32274687"><sentence text="Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin."><entity charOffset="80-90" id="DDI-PubMed.32274687.s1.e0" text="Colchicine" /><entity charOffset="95-109" id="DDI-PubMed.32274687.s1.e1" text="Clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s1.e0" e2="DDI-PubMed.32274687.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s1.e0" e2="DDI-PubMed.32274687.s1.e1" /></sentence><sentence text="Colchicine is currently approved for the treatment of gout and familial Mediterranean fever, among other conditions"><entity charOffset="0-10" id="DDI-PubMed.32274687.s2.e0" text="Colchicine" /></sentence><sentence text=" Clarithromycin, a strong inhibitor of CYP3A4 and P-glycoprotein, dramatically increases colchicine's half-life, augmenting the risk of a life-threatening adverse reaction when used inadvertently with colchicine"><entity charOffset="1-15" id="DDI-PubMed.32274687.s3.e0" text="Clarithromycin" /><entity charOffset="201-211" id="DDI-PubMed.32274687.s3.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.32274687.s3.e0" e2="DDI-PubMed.32274687.s3.e0" /><pair ddi="true" e1="DDI-PubMed.32274687.s3.e0" e2="DDI-PubMed.32274687.s3.e1" /></sentence><sentence text="" /><sentence text="The aim of this study was to examine the evidence and clinical implications of concomitant use of colchicine and clarithromycin"><entity charOffset="98-108" id="DDI-PubMed.32274687.s5.e0" text="colchicine" /><entity charOffset="113-127" id="DDI-PubMed.32274687.s5.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s5.e0" e2="DDI-PubMed.32274687.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s5.e0" e2="DDI-PubMed.32274687.s5.e1" /></sentence><sentence text="" /><sentence text="Case reports of colchicine-clarithromycin co-administration were searched using the FDA's Adverse Event Reporting System (FAERS) database"><entity charOffset="16-26" id="DDI-PubMed.32274687.s7.e0" text="colchicine" /><entity charOffset="27-41" id="DDI-PubMed.32274687.s7.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s7.e0" e2="DDI-PubMed.32274687.s7.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s7.e0" e2="DDI-PubMed.32274687.s7.e1" /></sentence><sentence text=" PubMed, EMBASE, and Web of Science electronic databases were also searched from January 2005 through November 2019 for articles reporting colchicine-clarithromycin concomitant use"><entity charOffset="139-149" id="DDI-PubMed.32274687.s8.e0" text="colchicine" /><entity charOffset="150-164" id="DDI-PubMed.32274687.s8.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s8.e0" e2="DDI-PubMed.32274687.s8.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s8.e0" e2="DDI-PubMed.32274687.s8.e1" /></sentence><sentence text=" Individual reports were reviewed to identify consequences of coadministration, dose, days to onset of interaction, symptoms, evidence of renal disease, time to resolution of symptoms, and Drug Interaction Probability Scale (DIPS) rating" /><sentence text="" /><sentence text="The FAERS search identified 58 reported cases, nearly 53% of which were from patients aged between 65 and 85 years" /><sentence text=" Of 30 reported deaths, 11 occurred in males, and 19 in females" /><sentence text=" Other frequent complications reported in FAERS included diarrhea (31%), pancytopenia (22%), bone marrow failure (14%), and vomiting (14%)" /><sentence text=" From published literature, we identified 20 case reports of concomitant exposure, 19 of which were rated 'probable' and one 'possible' according to DIPS rating" /><sentence text=" Of these cases, four 'probable' patients expired" /><sentence text=" The documented onset of colchicine toxicity occurred within 5 days of starting clarithromycin, and death within 2 weeks of concomitant exposure"><entity charOffset="25-35" id="DDI-PubMed.32274687.s16.e0" text="colchicine" /><entity charOffset="80-94" id="DDI-PubMed.32274687.s16.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s16.e0" e2="DDI-PubMed.32274687.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s16.e0" e2="DDI-PubMed.32274687.s16.e1" /></sentence><sentence text="" /><sentence text="Clinical manifestations of colchicine-clarithromycin interaction may resemble other systemic diseases and may be life threatening"><entity charOffset="27-37" id="DDI-PubMed.32274687.s18.e0" text="colchicine" /><entity charOffset="38-52" id="DDI-PubMed.32274687.s18.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.32274687.s18.e0" e2="DDI-PubMed.32274687.s18.e0" /><pair ddi="false" e1="DDI-PubMed.32274687.s18.e0" e2="DDI-PubMed.32274687.s18.e1" /></sentence><sentence text=" Understanding this clinically meaningful interaction can help clinicians avoid unsafe medication combinations" /><sentence text="" /></document>